Pfizer Says Glenmark’s Generic Bid Infringes Cancer Drug Patent

Glenmark Pharmaceuticals Ltd.‘s application to manufacture a generic version of Pfizer Inc.‘s kidney cancer drug Inlyta infringes Pfizer’s patent, a June 26 complaint in the District of Delaware says.

Glenmark filed an Abbreviated New Drug Application with the Food and Drug Administration to make and sell a generic version of the drug May 13.

Pfizer owns U.S. Patent No. 8,791,140, which covers a formulation of axitinib to treat advanced renal cell carcinoma, and sells the drug as Inlyta.

Pfizer says that because its patent hasn’t yet expired, the submission of the drug application constitutes patent infringement under the ...